KRAS and cancer: We observed statistically significant shortening of telomeres in cancer tissue, irrespective of age group, gender, location (right/left sided), pathological diagnosis, staging, grading, mutational status (KRAS rs112445441 and BRAFv600E) or MSI status (Table 2).